MYometrial Lesion UltrasouNd And mRi (MYLUNAR)

June 16, 2023 updated by: CICCARONE FRANCESCA, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

A monocentric prospective observational study aimed at assessing the accuracy of a diagnostic algorithm to pre-operatively identify uterine sarcomas..

Primary Aim:The primary outcome is to evaluate the accuracy (sensitivity/specificity) of "Positive Orange Criteria" category in predicting uterine sarcoma and STUMP in the population of patients with > 3 cm myometrial lesions.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

INTRODUCTION

Uterine sarcomas are rare malignant tumors arising from the mesenchymal tissues of the uterus including the endometrial stroma, uterine muscle and connective tissue. They represent 1% of female genital tract malignancies and 3-7% of all uterine malignances with a worldwide annual incidence of 1.55-1.95 per 100.000 women. Malignant mesenchimal tumors include: uterine leiomyosarcoma (LMS), endometrial stromal sarcoma (ESS), and undifferentiated uterine sarcoma (UUS), and other (eg adenosarcoma, epithelioid sarcoma, STUMP). The current WHO classification also includes a smooth muscle tumor with features that preclude an unequivocal diagnosis of leiomyosarcoma, but do not fulfill the criteria for leiomyoma, or its variants, therefore is defined as smooth uterine muscle of uncertain malignant potential (STUMP). While most STUMP patients have good outcomes, unexpected aggressive behavior can be seen in some of the tumors.

The mean age at diagnosis is approximately 60 years old. However, uterine sarcomas have been diagnosed in women as young as 20 years old . The prevalence of sarcoma in women undergoing hysterectomy or myomectomy for a myometrial mass, is approximately 0.001 percent (1 in 1000) (Parker 94), with a range from 0.005 (1 in 2000) to 0.28 percent (1 in 352). , The discrimination between benign and malignant myometrial lesions is clinically relevant to plan the optimal management (surgery versus medical treatment) and to define the most appropriate surgical approach.

However, the diagnosis of uterine sarcomas or STUMP is a challenge and no validated clinical or radiological criteria can accurately distinguish benign from malignant myometrial tumors.

In particular, data on the ultrasound features of uterine sarcomas are scarce and they are mainly based on retrospective case series. The role of CT(Computed Tomography) has generally been limited to identify extrauterine disease, including local spread within the pelvis and metastatic disease. MRI (Magnetic Resonance Imaging) )represents an accurate diagnostic imaging modality in the assessment of gynecological pathologies with high soft tissue contrast, large field-of-view and multiplanar imaging capabilities; however, no accurate diagnostic criteria have been validated to discriminate between benign and malignant myometrial lesions.

To the best of our knowledge, no large prospective studies have been carried on to assess a diagnostic algorithm to predict the malignant histology of myometrial lesions.

PURPOSES AND OBJECTIVES OF THE CLINICAL TRIAL

Primary aim:

The primary outcome is to evaluate the accuracy (sensitivity/specificity) of "Positive Orange Criteria" category in predicting uterine sarcoma and STUMP in the population of patients with > 3 cm myometrial lesions.

Secondary aims:

  1. To describe the clinical history of patients with myometrial lesions, assessed on ultrasound, and conservatively managed.
  2. To assess the accuracy of subjective assessment of an experienced ultrasound examiner in detecting uterine sarcomas and STUMP in women with at least one >3 cm myometrial lesion.
  3. To compare clinical and ultrasound characteristics of patients with benign myometrial lesion versus those with uterine sarcomas and STUMP, histologically confirmed.
  4. To compare clinical and Magnetic Resonance (MR) characteristics of patients with benign myometrial lesions versus those with uterine sarcomas and STUMP, histologically confirmed.
  5. To compare the accuracy of the subjective assessment of an ultrasound examiner versus that of a MR reader in detecting uterine sarcomas and STUMP in women triaged for surgery ("Orange group").

EXPERIMENTAL DESIGN

  • Type of study: Monocentric, prospective, observational study
  • Setting: Department of Woman and Child Health, Fondazione Policlinico Universitario A. Gemelli, IRCSS, Roma.
  • Estimated study period: Three years for the enrollment and additional two years for the completion of follow-up.

STUDY POPULATION SAMPLE SIZE

This study is dimensioned on the hypothesis that "Positive Orange criteria" category has a sensitivity of at least 90% in identify patients with uterine sarcoma and STUMP among patients with at least one >3 cm myometrial lesion, against a null hypothesis of 65% [143]. Considering the prevalence of uterine sarcoma in this population 1.55%, as per our previous experience, to demonstrate an increase in sensitivity of 25% with a 90% power and bilateral alpha error=5%, 2000 patients (with at least one ≥ 3 cm myometrial lesion) with 30 sarcomas are needed. Considering a 15% of drop-out (patients evaluated but not completing the observation), 2353 patients will be enrolled. With this number of patients, the study will have 100% power in demonstrating a similar increase in the specificity of the "Positive Orange criteria" category with an alpha error=0.05. (PASS v11)

IDENTIFICATION PARAMETERS

A myometrial lesion with the largest diameter >3 cm represents the target lesion. In case of multiple myometrial lesions with similar ultrasound morphology, the largest tumor will be selected as target lesion. In case of multiple myometrial lesions with different ultrasound morphology, the "target lesion" will be identified by the ultrasound examiner on the basis of the parameters subjectively considered suspicious for malignancy.

WITHDRAWAL PROCEDURES

The patient may choose not to take part in this study. The patient may choose to have US revaluation or surgery without enrolling in this study. The patient may choose to receive other therapy, if available. In all cases, the woman receive appropriate medical care, including treatment for bleeding, pain or other symptoms.

SUBJECT TREATMENT

All women enrolled in the study will be managed according to the following algorithm (Figure 1. Clinical and Diagnostic Algorithm).

Patients will be assessed by a Green Card (Figure 2. Green Card) to check the eventual presence of at least one of the following clinical and/or ultrasound characteristics:

  • Maximum size of the lesion ≥ 5cm;
  • Symptoms (abdominal and/or pelvic pain, sensation of pressure, abdominal distension, infertility (>12 months), two or more abortions;
  • Largest diameter rapid growth (Growth >30% per year);
  • Irregular cystic areas;

  • Color Score 4.

    • If no Green Card criteria is fulfilled (Negative Green Criteria), the patient will receive an annual telephone follow up for 2 years.
    • If one or more Green Card criteria is present (Positive Green Criteria), a dedicated clinical and ultrasound paper form (Appendix 1. MYLUNAR Paper Form) will be fulfilled in order to check the presence of the criteria described in the Orange Card (Figure 3. Orange Card):

  • Anamnestic and clinical characteristics:

    • Age ≥ 45 years old
    • Symptoms (abnormal uterine bleeding; abdominal and/or pelvic pain; sensation of pressure; Abdominal distension)
    • LDH (Lactate dehydrogenase) > 250 UI/L (if known)

  • Ultrasound characteristics:

    • Maximum size of the lesion ≥ 8cm
    • Largest diameter rapid growth (Growth >30% per year)
    • Irregular margins of the lesion
    • Presence of irregular cystic areas
    • Absence of acoustic shadow
    • Color Score 4

    • "Cooked" aspect

      • If at least two Orange Card criteria (including at least one ultrasound parameter) are present (Positive Orange Criteria), the patient will be examined by means of Magnetic Resonance (MRI) within 30 days and triaged to surgery (to be performed within 60 days since the enrollment in the study). A dedicated MRI paper form will be fulfilled (Appendix 2. MRI Paper Form) Histology of the target myometrial lesion will be considered as the gold standard parameter.
      • In case of "negative Orange Criteria" (i.e. no Orange Card criteria, or only one Orange Card criteria, or only Orange clinical criteria) the patient will be scheduled for longitudinal follow up at 6, 12 and 24 months. At each follow-up visit, a transvaginal ultrasound examination will be performed (using the MYLUNAR Paper Form) and the patient will be re-evaluated according to the Orange Card. In case of "positive Orange Criteria" the patient will be triaged to MRI and surgery. Eventual treatment for the myometrial lesion during the study period will be recorded and the outcome of these patients will be described separately.

Study Type

Observational

Enrollment (Estimated)

2353

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Italy
      • Rome, Italy, 00191
        • Recruiting
        • Fondazione Policlinico Agostino Gemelli
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Patients with a myometrial lesion with the largest diameter >3 cm that represents the target lesion

Description

Inclusion Criteria:

  • Consecutive patients admitted to our Department for transvaginal ultrasound examination, in whom a myometrial lesion > 3cm in size is detected.
  • Informed consent form signed by the patient.

Exclusion Criteria:

  • Patients undergoing medical treatment for myometrial lesion;
  • Patients previously treated with hormonal therapy including estroprogestin in the last six months;
  • Patients previously treated by embolization

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
WHITE
If no Green Card criteria is fulfilled (Negative Green Criteria), the patient will receive an annual telephone follow up for 2 years.
Diagnostic test: Ultrasound
Intervention: Diagnostic Test Ultrasound Ultrasound investigating the following characteristics: Maximum size of the lesion ≥ 8cm; Largest diameter rapid growth (Growth >30% per year); Irregular margins of the lesion; Presence of irregular cystic areas; Absence of acoustic shadow; Color Score 4; "Cooked" aspect; ]
GREEN

Patients will be assessed by a Green Card to check the eventual presence of at least one of the following clinical and/or ultrasound characteristics.

  • If one or more Green Card criteria is present (Positive Green Criteria), a dedicated clinical and ultrasound paper form will be fulfilled in order to check the presence of the criteria described in the Orange Card
  • In case of "negative Orange Criteria" (no Orange Card criteria, or only one Orange Card criteria, or only Orange clinical criteria) the patient will be scheduled for longitudinal follow up at 6, 12 and 24 months. At each follow-up visit, a transvaginal ultrasound examination will be performed (using the MYLUNAR Paper Form) and the patient will be re-evaluated according to the Orange Card. In case of "positive Orange Criteria" the patient will be triaged to MRI and surgery. Eventual treatment for the myometrial lesion during the study period will be recorded and the outcome of these patients will be described separately.
Diagnostic test: Ultrasound
Intervention: Diagnostic Test Ultrasound Ultrasound investigating the following characteristics: Maximum size of the lesion ≥ 8cm; Largest diameter rapid growth (Growth >30% per year); Irregular margins of the lesion; Presence of irregular cystic areas; Absence of acoustic shadow; Color Score 4; "Cooked" aspect; ]
ORANGE
- If at least two Orange Card criteria (including at least one ultrasound parameter) are present (Positive Orange Criteria), the patient will be examined by means of Magnetic Resonance (MRI) within 30 days and triaged to surgery (to be performed within 60 days since the enrollment in the study). A dedicated MRI paper form will be fulfilled Histology of the target myometrial lesion will be considered as the gold standard parameter.
Diagnostic test: Ultrasound
Intervention: Diagnostic Test Ultrasound Ultrasound investigating the following characteristics: Maximum size of the lesion ≥ 8cm; Largest diameter rapid growth (Growth >30% per year); Irregular margins of the lesion; Presence of irregular cystic areas; Absence of acoustic shadow; Color Score 4; "Cooked" aspect; ]
Diagnostic test: MRI

Diagnostic Test: MRI; MRI investigating the following carachteristics:

TARGET LESION Maximum diameter; Borders; Signal intensity on T2WI; Heterogeneity on T2WI; Cystic alteration(s); Cystic alteration(s) borders; Hemorrhage; T2 dark" area(s); Flow voids; Signal intensity on DWI(b-1000); ADC value; ≥ 1,23 Signal intensity on contrasted images Intensity [relative to myometrium] (Hyper- / Hypo- / Iso- intense) Heterogeneity (Homogeneous / Heterogeneous) Unenhanced area(s) Presence (Present / Absent) Location (Central / None or non-central) 1 Tumour - myometrium contrast ratio on T2WI [SItumour - SImyometrium / SImyometrium]

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Diagnostic algorithm in predicting uterine sarcoma and STUMP
Time Frame: January 2019- January 2024
the accuracy (sensitivity/specificity) of "Positive Orange Criteria" category in predicting uterine sarcoma and STUMP in the population of patients with > 3 cm myometrial lesions.
January 2019- January 2024

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Collaborators

Prof. Antonia Testa
Dr. Daniela Romualdi
Dr. Francesca Ciccarone

Investigators

  • Principal Investigator: Francesca Ciccarone, M.D., Fondazione Policlinico Agostino Gemelli

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 17, 2019

Primary Completion (Actual)

January 17, 2022

Study Completion (Estimated)

January 17, 2024

Study Registration Dates

First Submitted

October 9, 2019

First Submitted That Met QC Criteria

October 9, 2019

First Posted (Actual)

October 10, 2019

Study Record Updates

Last Update Posted (Estimated)

June 19, 2023

Last Update Submitted That Met QC Criteria

June 16, 2023

Last Verified

June 1, 2023

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 2370

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sarcoma Uterus

Clinical Trials on Ultrasound

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe